Seunghee Yeon

Title: Seunghee Yeon: Inventor in Stem Cell-Based Cardiac Safety Testing

Introduction

Seunghee Yeon is an inventor based in Seoul, South Korea, whose work includes a patent for evaluating the cardiac safety of drugs using cardiomyocytes derived from human stem cells. The patent record lists one patent associated with Yeon.

Latest Patents

Yeon’s patent, “Methods for Evaluating Cardiac Safety of Drug Using Cardiomyocytes Derived from Human Stem Cells,” describes a method for assessing potential cardiac effects of drugs. It involves differentiating human stem cells into cardiomyocytes, preparing fibronectin in Dulbecco’s phosphate-buffered saline at a concentration of 50 μg/ml, and applying the solution to selected wells of a multi-electrode array (MEA) plate. After adding culture medium, the method measures changes in beat rate, spike amplitude, and field potential duration, comparing results according to whether the drug under evaluation has been added.

Career Highlights

Yeon is associated with Nexel Co., Ltd. The patented method uses human stem cell-derived cardiomyocytes and MEA measurements to evaluate drug-related changes in cardiac activity.

Collaborations

The provided information identifies Donghun Woo and Jieun An as Yeon’s coworkers. No further details about their roles or specific contributions to the patent are available in the supplied data.

Conclusion

Seunghee Yeon’s patent describes a stem cell-based approach to drug cardiac safety assessment, using measurable electrical activity in cardiomyocytes to evaluate potential drug effects.